Exudative Age-Related Macular Degeneration: A Case Report and Review of the Literature

Chabbar, Imane; Serghini, Louai; Boulanouar, A.; Berraho, A.

doi:10.36348/sjmps.2020.v06i06.010

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The treatment of subfoveal CNV is no longer performed with TLP because it induces immediate and iatrogenic central scotoma [ 106 ]. Since 2006, both TLP and dynamic phototherapy have been replaced by anti-angiogenic injections in AMD treatment [ 110 ].…”

Section: Exudative Age-related Macular Degeneration (Wet Amd)mentioning

confidence: 99%

Exudative versus Nonexudative Age-Related Macular Degeneration: Physiopathology and Treatment Options

Fernandes

Zielińska

Santos

et al. 2022

IJMS

View full text Add to dashboard Cite

Age-related macular degeneration (AMD) is an eye disease typically associated with the aging and can be classified into two types—namely, the exudative and the nonexudative AMD. Currently available treatments for exudative AMD use intravitreal injections, which are associated with high risk of infection that can lead to endophthalmitis, while no successful treatments yet exist for the nonexudative form of AMD. In addition to the pharmacologic therapies administered by intravitreal injection already approved by the Food and Drug Administration (FDA) in exudative AMD, there are some laser treatments approved that can be used in combination with the pharmacological therapies. In this review, we discuss the latest developments of treatment options for AMD. Relevant literature available from 1993 was used, which included original articles and reviews available in PubMed database and also information collected from Clinical Trials Gov website using “age-related macular degeneration” and “antiangiogenic therapies” as keywords. The clinical trials search was limited to ongoing trials from 2015 to date.

show abstract

Section: Exudative Age-related Macular Degeneration (Wet Amd)mentioning

confidence: 99%